What Is TB-500?
TB-500 is a synthetic version of a fragment of Thymosin Beta-4 — a protein your body actually produces naturally. Thymosin Beta-4 is found in virtually every cell in the human body and plays a fundamental role in how cells move, organize, and respond to injury.
The TB-500 peptide specifically targets the part of Thymosin Beta-4 that researchers believe is responsible for most of its biological activity. By studying this isolated fragment, researchers can work with a simpler, more stable compound while still capturing the core mechanism they are interested in.
The Actin Connection — Why This Matters
To understand TB-500, you need to know one thing about cell biology: actin is the scaffolding your cells are built on. It forms the internal skeleton that gives cells their shape, and — critically — it allows cells to move.
When you get injured, your body sends repair cells to the site. Fibroblasts rebuild connective tissue. Keratinocytes resurface wounds. Endothelial cells build new blood vessels. All of these cells need to migrate — to physically move from where they are to where they are needed. That movement depends on actin.
TB-500 binds to a form of actin called G-actin (the building block form) and regulates the balance between building and breaking down actin filaments. In doing so, it appears to facilitate cell migration — essentially making it easier for repair cells to get to where they need to go.
What the Research Shows
A widely cited 1999 study found that TB-500 (studied as Thymosin Beta-4) accelerated wound closure in mouse models by approximately 41% compared to controls. Subsequent research extended these findings to cardiac tissue, where TB-500 was observed to have potential protective effects following simulated heart attack conditions in animal models.
Hair follicle research is another area — multiple rodent studies have associated TB-500 with hair follicle activation, though this line of research is less developed than the wound healing work.
Like BPC-157, virtually all TB-500 research has been conducted in animals. Human clinical data is essentially absent as of 2026.
Why TB-500 and BPC-157 Are Often Studied Together
They work through different mechanisms. BPC-157 research focuses primarily on blood vessel formation and growth factor interactions. TB-500 focuses on cellular movement and structural reorganization. These are genuinely complementary processes — different phases of the same healing cascade.
Think of it this way: BPC-157 may help build the infrastructure (new blood vessels) that an injury site needs. TB-500 may help the repair crew (mobile cells) get to the site and do their work. They are not redundant — they address different bottlenecks in the same process, which is why researchers and physicians often consider them as a pair.
2026 Status
TB-500, like BPC-157, is currently Category 2 — not available through compounding pharmacies. Both are on the agenda for the July 2026 FDA PCAC meeting. A reclassification would allow licensed physicians to prescribe both compounds through regulated 503A compounding pharmacies for the first time.